USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
AVANT IMMUNOTHERAPEUTICS, INC.
Address:
AVANT IMMUNOTHERAPEUTICS, INC.
119 4TH AVE
NEEDHAM, MA 02494 0272
Phone:
(781) 433-0771
URL:
N/A
EIN:
133191702
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $699,887.00 5
SBIR Phase II $750,000.00 1

Award List:

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$218,442.00
Agency:
HHS
Principal Investigator:
David T. Beattie
Abstract:
N/a

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$103,263.00
Agency:
HHS
Principal Investigator:
Carolyn L. Pettey
Abstract:
Not Available This proposed program is directed towards development and evaluation of a fiber optic sensor for detection of ammonia in the 100 ppb - 500 ppm range. The sensor technology is based on immobilized triphenylmethane dyes which serve as the chemical transduc

LIVE ATTENUATED BACTERIAL VACCINES AGAINST ANTHRAX

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$120,511.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The ability to prepare anthrax spores inexpensively and deliver them in an aerosol form, and the high mortality rate of inhalation anthrax, has made Bacillus anthracis one of the most feared agents of biological warfare and terrorism. Despite recent advances in… More

Feasibility Evaluation of an Oral Typhoid Fever Vaccine

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$126,861.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Ty800 is a live attenuated Salmonella typhi organism intended to be used as a prophylactic single dose oral vaccine for Typhoid fever. Ty800 may have advantages in several respects to current Typhoid fever vaccines, and consequently could be a significant advance… More

Live Attenuated Salmonella Vaccine Against Campylobacter

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$130,810.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The bacterium, Campylobacter jejuni, is a major cause of diarrheal illness in both the developed and developing world. It is estimated that Campylobacter may affect as many as 400 million people and cause 14 percent of all diarrheal cases worldwide. There is… More

Development and cGMP Manufacture of a Vitrified Typhoid Vaccine

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$750,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Typhoid fever is an infectious disease that annually afflicts an estimated 16 million people worldwide, resulting in 600,000 deaths. The etiologic agent of typhoid fever, Salmonella typhi (S. typhi), is transmitted to humans by the fecal-oral route through… More